Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize the activity of dimeric compounds at the structural, biochemic...
Saved in:
Main Authors: | Ahmed F. Salem (Author), Luca Gambini (Author), Parima Udompholkul (Author), Carlo Baggio (Author), Maurizio Pellecchia (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical and Toxicology Assessment of ALW-II-41-27, an Inhibitor of the Eph Receptor A2 (EphA2)
by: Theodore J. Kottom, et al.
Published: (2024) -
Homocysteine Impairs Endothelial Cell Barrier Function and Angiogenic Potential via the Progranulin/EphA2 Pathway
by: Dan Tian, et al.
Published: (2021) -
COMPLEMENTARY EXPRESSION OF EphA7 AND SCO-SPONDIN DURING POSTERIOR COMMISSURE DEVELOPMENT
by: Karen eStanic, et al.
Published: (2014) -
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
by: Walid Kamoun, et al.
Published: (2020) -
EphA2 is a biomarker of hMSCs derived from human placenta and umbilical cord
by: Shih-Pei Shen, et al.
Published: (2015)